Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.
2.
3.

Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.

Andrianov AM, Veresov VG.

J Biomol Struct Dyn. 2007 Jun;24(6):597-608.

PMID:
17508782
4.

Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gp120 V3 loop.

Andrianov AM, Anishchenko IV, Tuzikov AV.

J Chem Inf Model. 2011 Oct 24;51(10):2760-7. doi: 10.1021/ci200255t.

PMID:
21888425
5.

Structural analysis of the envelope gp120 V3 loop for some HIV-1 variants circulating in the countries of Eastern Europe.

Andrianov AM, Kornoushenko YV, Anishchenko IV, Eremin VF, Tuzikov AV.

J Biomol Struct Dyn. 2013;31(7):665-83. doi: 10.1080/07391102.2012.706455.

PMID:
22888999
6.
7.

Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.

Wagner R, Modrow S, Böltz T, Fliessbach H, Niedrig M, von Brunn A, Wolf H.

Arch Virol. 1992;127(1-4):139-52.

PMID:
1456889
8.

Conformational preferences of the HIV-1 principal neutralizing determinant.

Andrianov AM.

J Biomol Struct Dyn. 2005 Dec;23(3):267-82.

PMID:
16218754
9.

Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study.

Andrianov AM, Kashyn IA, Tuzikov AV.

J Biomol Struct Dyn. 2014 Dec;32(12):1993-2004. doi: 10.1080/07391102.2013.848825.

PMID:
24251545
10.
12.

Immunophilins and HIV-1 V3 loop for structure-based anti-AIDS drug design.

Andrianov AM.

J Biomol Struct Dyn. 2009 Feb;26(4):445-54.

PMID:
19108583
13.

Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.

Yuan Y, Yokoyama M, Maeda Y, Terasawa H, Harada S, Sato H, Yusa K.

PLoS One. 2013 Jun 28;8(6):e65115. doi: 10.1371/journal.pone.0065115.

16.
18.
19.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

Items per page

Supplemental Content

Support Center